A perspective published in PLOS Medicine by Chao, Gilden, and Wadden notes that GLP-1 and dual-agonist therapies have transformed obesity care, with efficacy that rivals some bariatric procedures in selected trials as demonstrated in major Phase 3 programs while the system-level challenges of capacity, monitoring, and access remain significant
Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists
Your gastric emptying (the speed at which your stomach releases food into your small intestine) also slows down, meaning food stays in your stomach longer and you feel satisfied on smaller portions
Shutdowns tend not to reprice the fundamental path of earnings, inflation, or the Fed which are still the dominant drivers of asset performance
This prolonged, supraphysiological stimulation results in greater glucose-lowering effects, more pronounced appetite suppression, and clinically significant weight loss that varies by medication and dose: approximately 5-8% with liraglutide 3 mg, 10-15% with semaglutide 2.4 mg, and 15-22% with tirzepatide at higher doses